On September 27, Huadong Medicine announced that its independently developed Class 1 innovative drug, the oral small-molecule ...

VigorHorse new botanical supplement combines multiple plant extracts, L-arginine and a small amount of caffeine in a once-daily gummy format ...

Eli Lilly expands its obesity drug lead as Novo Nordisk faces patent cliffs for Wegovy and Ozempic, prompting a pipeline ...

The story includes details about the Season 1 finale “Spoiler: Filmed In Front Of a Live Studio Audience” of HBO Max’s Stuart ...

Lipfendra and promising intismeran autogene trial results support Merck's multi-year portfolio renewal prospects amid patent ...

AURORA, CO / ACCESS Newswire / September 22, 2026 / Rezera Inc. (the "Company"), a clinical-stage biotechnology company ...

NVO tumbled about 8% as its Capital Markets Day failed to convince investors despite plans for more than five “multi-blockbusters” by 2030. ・Viking’s injectable VK2735 produced up to 14.7% weight loss ...

"Completing dose escalation for R-5780 is a meaningful step in translating our novel immunotherapy approach into a potential option for people fighting cancer," stated Gary Fanger, President and CEO ...

Novo Nordisk seeks growth beyond obesity drugs, aiming for five blockbuster products by 2030, but signals a slower, more mature outlook ahead.

Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular ...

Novo Nordisk (NVO) shares dropped 9% Monday after revealing 2030 growth targets aligned with pharma peers and plans for five new blockbuster drug launches.

Novo Nordisk is targeting more than DKK 150 billion, or approximately $23 billion, in annual sales from pipeline medicines by ...